Open AccessClusterin role in hepatocellular carcinoma patients treated with oxaliplatin
Author(s) -
Xiumei Wang,
Yongqiang Liu,
Qiong Qin,
Ti Zheng
Publication year - 2020
Publication title -
bioscience reports
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.938
H-Index - 77
eISSN - 1573-4935
pISSN - 0144-8463
DOI - 10.1042/bsr20200071
Subject(s) - clusterin , hepatocellular carcinoma , medicine , immunohistochemistry , oncology , proportional hazards model , biomarker , gastroenterology , stage (stratigraphy) , apoptosis , biology , paleontology , biochemistry
To explore the prognostic value of clusterin (CLU) in hepatocellular carcinoma (HCC) patients treated with oxaliplatin (OXA).
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom